Can early liver fat accumulation and fibrosis be reversed by addressing the underlying metabolic causes?

Liver fat accumulation (known in medical circles as MASLD/NASH or MASH) is largely reversible in its early stages if the underlying causes are addressed. A study of 293 patients with biopsy-confirmed fatty liver inflammation showed that those who lost at least 10% of their body weight through lifestyle changes saw complete resolution of liver inflammation in 90% of cases. In 45% of patients, a measurable regression of fibrosis (scar tissue) was visible on a repeat biopsy. Even at just 5% weight loss, more than half of the patients achieved complete resolution of liver inflammation. The effect is dose-dependent: greater weight loss produces better outcomes.

The reverse is equally true: a large international study of 10,014 patients showed that those who gained more than 5% of their body weight had nearly twice the risk of serious liver complications and further stiffening of the liver. Those who managed to reverse their obesity had a risk comparable to people who had never been obese. This is a concrete argument for stabilising or reducing weight, even when full normalisation is not immediately achievable.

How that weight loss is achieved also matters. A Mediterranean diet produced modest but measurable improvements in weight and liver enzymes in a meta-analysis of randomised studies. Resistance training stood out in particular: it produced a greater average reduction in the liver enzyme ALT than aerobic exercise, suggesting that muscle training also directly reduces liver inflammation. Aerobic exercise was more effective for waist circumference. The thresholds for the liver itself are: 5% weight loss reduces liver fat, 7% improves inflammation, and only from 10% onwards does fibrosis stabilise or reverse, as summarised by a review study.

Those who respond insufficiently to lifestyle changes may consider medication. A drug called resmetirom, which activates the thyroid receptor in the liver, became the first medication to receive provisional approval on the basis of improvements in both liver histology and fibrosis, without requiring weight loss. GLP-1 agonists (a class also used in diabetes and obesity, including semaglutide) improve liver fat accumulation and inflammation, but did not demonstrably reduce fibrosis in the clinical data discussed. Pioglitazone offers some benefit for fibrosis, but this has only been demonstrated in post-hoc analyses, and it is associated with modest weight gain. An experimental mRNA therapy that reversed liver fat accumulation and fibrosis in mice has not yet been tested in humans.

Lifestyle intervention, with emphasis on a Mediterranean low-calorie diet, regular physical activity and no alcohol, is the first step in treatment. Medications are supplementary, for people who do not make sufficient progress with lifestyle changes alone.